Aura Biosciences, Inc. (AURA) — Annual Report

Key Insights

• Aura Biosciences, Inc. is a late-stage biotechnology company focused on developing novel therapies for ocular and oncologic indications. The company has made progress on its clinical pipeline, including entering into a collaboration agreement with Dr. John Schiller.
• Aura has raised additional capital through follow-on offerings and at-the-market offerings, which should provide funding to support its ongoing research and development activities.
• The company has entered into various licensing and supply agreements, including with LI-COR, Inc., which provide access to key technologies and support its product development efforts.